
News|Videos|July 11, 2024
Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis
Key opinion leaders share their approach to treatment sequencing for patients with multiple sclerosis (MS), taking into account comorbidities such as cardiovascular diseases, risk of infection, liver damage, and cancer as well as considering factors like planned pregnancy or advanced age.
Advertisement
Episodes in this series

- How do you choose between different therapies for moderate MS in the context of other conditions?
- Patients with comorbidities (eg, cardiovascular diseases, risk of infection, liver damage, cancer)
- Patients considering pregnancy in the near future
- Patients who have late onset MS or are older
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
New Phase 3 Study to Evaluate Remibrutinib in Generalized Myasthenia Gravis Treatment
2
Early-Stage Study to Test CD19 CAR T-Cell Therapy YTB323 in Myasthenia Gravis
3
Jessica Neil, PA, on the Evolution of Patients With Headache
4
FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency
5
































